Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Therapy

Biosimilars in rheumatology — why, how and when in 2017

Nature Reviews Rheumatology volume 13, pages 701–703 (2017)Cite this article

Subjects

Biosimilar therapeutics for immune-mediated disease are approved in many countries and are increasingly being utilized in clinical practice. Although much has been written about the effectiveness and safety of biosimilars, less focus has been placed on why, how and when (or when not) to use these medications — until now.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Curtis, J. R. & Singh, J. A. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 33, 679–707 (2011).

    Article  CAS  Google Scholar 

  2. Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68, 1–26 (2016).

    PubMed  Google Scholar 

  3. Cohen, S. & Kay, J. Biosimilars: implications for rheumatoid arthritis therapy. Curr.Opin.Rheumatol. 29, 260–268 (2017).

    Article  Google Scholar 

  4. Kay, J. et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211937, (2017).

  5. Jorgensen, K. K. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389, 2304–2316 (2017).

    Article  Google Scholar 

  6. US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. FDA https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/UCM537135 (2017).

Download references

Author information

Authors and Affiliations

  1. Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 810, Dallas, 75231, Texas, USA

    Roy Fleischmann

Authors
  1. Roy Fleischmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roy Fleischmann.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fleischmann, R. Biosimilars in rheumatology — why, how and when in 2017. Nat Rev Rheumatol 13, 701–703 (2017). https://doi.org/10.1038/nrrheum.2017.179

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2017.179

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing